摘要
背景:多发性骨髓瘤患者患有免疫系统失调,针对免疫系统(例如单克隆抗体或特异性细胞治疗如CAR-T细胞)的新治疗方案进入临床实践,但是耗尽的免疫系统阻碍了更有效的免疫治疗。针对微环境中的免疫功能障碍可能是免疫介导治疗的潜在靶标。 方法:在这里,我们回顾当前关于在耗尽的T和B细胞表面表达的程序性死亡1(PD-1)受体的文献和知识,其配体PD-L1在骨髓瘤细胞上表达并抑制T细胞介导细胞凋亡。 结果:程序性死亡1(PD-1)受体在耗尽的T和B细胞表面表达,其配体PD-L1在骨髓瘤细胞上表达并抑制T细胞介导的细胞凋亡。近来,通过单克隆抗体抑制这种“检查点”已经显示在实体瘤和恶性淋巴瘤中的高活性。在多发性骨髓瘤患者中,PD-L1在骨髓瘤细胞上过表达,PD1在T细胞上表达,表明PD-1 / PD-L1在免疫抑制微环境中起主要作用。 结论:使用抗PD-1 / PD-L1策略的免疫治疗是多发性骨髓瘤患者的有希望的治疗方案。
关键词: Coinhibitory分子PD-1,微环境,多发性骨髓瘤,T细胞介导的凋亡,PD-L1,免疫抑制。
Current Cancer Drug Targets
Title:Coinhibitory Molecule PD-1 as a Therapeutic Target in the Microenvironment of Multiple Myeloma
Volume: 17 Issue: 9
关键词: Coinhibitory分子PD-1,微环境,多发性骨髓瘤,T细胞介导的凋亡,PD-L1,免疫抑制。
摘要: Background: Patients with Multiple Myeloma suffer from dysregulation of the immune system and new therapeutic options targeting the immune systems such as monoclonal antibodies or specific Cell therapy such as CAR-T cells have entered clinical practice, but the exhausted immune system hampered a more effective immunotherapy. Targeting the immunological dysfunction in the microenviroment might be a potential target for immune-mediated therapies.
Method: Here we review the current literature and knowledge about the programmed death 1 (PD-1) receptor which is expressed on the surface of exhausted T and B cells and its ligand PD-L1 is expressed on myeloma cells and inhibits T cell-mediated apoptosis.
Results: The programmed death 1 (PD-1) receptor is expressed on the surface of exhausted T and B cells and its ligand PD-L1 is expressed on myeloma cells and inhibits Tcell-mediated apoptosis. Inhibiting such “checkpoint” by monoclonal antibodies recently has been shown high activity in solid tumors and malignant lymphomas. In patients with multiple myelomaPD-L1 is overexpressed on myeloma cells and PD1 on T-cells suggesting an active role of PD-1/PD-L1 in the immunosuppressive microenvironment.
Conclusion: Immunotherapies using anti-PD-1/PD-L1 strategies are a promising treatment options for patients with multiple myeloma.
Export Options
About this article
Cite this article as:
Coinhibitory Molecule PD-1 as a Therapeutic Target in the Microenvironment of Multiple Myeloma, Current Cancer Drug Targets 2017; 17 (9) . https://dx.doi.org/10.2174/1568009617666170906170348
DOI https://dx.doi.org/10.2174/1568009617666170906170348 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cardiac Stem Cell Regeneration in Metabolic Syndrome
Current Pharmaceutical Design New Developments in Anthracycline-Induced Cardiotoxicity
Current Medicinal Chemistry Target Peptide Recognition by S100P Protein and Role of Central Linker Region and Dimer Interface
Protein & Peptide Letters An Overview of Piperazine Scaffold as Promising Nucleus for Different Therapeutic Targets
Current Pharmaceutical Design Natural Alkaloids and Diabetes Mellitus: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets 20-Hydroxyeicosatetraenoic Acid is a Potential Therapeutic Target in Cardiovascular Diseases
Current Drug Metabolism Pathophysiology, Diagnosis and Clinical Management of Hepatorenal Syndrome: From Classic to New Drugs
Current Vascular Pharmacology Evaluation of Cardiac Scan in Diagnosing Coronary-artery Disease
Current Medical Imaging Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment
Current Pharmaceutical Design COVID-19 Invades Several Important Organs other than the Lungs: Organs Crosstalk
Coronaviruses The Role of Negative Costimulators During Parasitic Infections
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of Oxidative Stress in Development of Cardiovascular Complications in Diabetes Mellitus
Current Vascular Pharmacology Doxorubicin Loaded Dextran-coated Superparamagnetic Iron Oxide Na-noparticles with Sustained Release Property: Intracellular Uptake, Phar-macokinetics and Biodistribution Study
Current Pharmaceutical Biotechnology Combating Neurodegenerative Diseases with the Plant Alkaloid Berberine: Molecular Mechanisms and Therapeutic Potential
Current Neuropharmacology Modulators of Inhibitor of Growth (ING) Family Expression in Development and Disease
Current Drug Targets Calreticulin in the Heart: From Embryological Development to Cardiac Pathology.
Current Molecular Medicine Clinical Applications of Creatine Supplementation on Paediatrics
Current Pharmaceutical Biotechnology Inflammatory Mechanisms in Atherosclerosis: The Impact of Matrix Metalloproteinases
Current Topics in Medicinal Chemistry Impact of N-acetylcysteine and Etodolac Treatment on Systolic and Diastolic Function in a Rat Model of Myocardial Steatosis Induced by High-Fat-Diet
Endocrine, Metabolic & Immune Disorders - Drug Targets Intracardiac Origin of Heart Rate Variability, Pacemaker Funny Current and their Possible Association with Critical Illness
Current Cardiology Reviews